Results 31 to 40 of about 1,448,905 (180)

Development of a Scalable Synthesis of a Bruton’s Tyrosine Kinase Inhibitor via C–N and C–C Bond Couplings as an End Game Strategy

open access: yes, 2016
A scalable and convergent synthesis of a BTK (Bruton’s tyrosine kinase) inhibitor has been developed. Synthetic routes to key intermediates were explored for the scale-up campaign, especially the process for 6-dimethylaminodihydroisoquinolinone, which ...
Keshab Sarma (1692565)   +8 more
core   +2 more sources

Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib

open access: yesJournal of Neurological Surgery Reports, 2022
Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired coagulation disorders such as leukemia ...
John Lynes   +7 more
doaj   +3 more sources

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

open access: yesNature Communications, 2020
PROTACs have emerged as promising therapeutic agents but their cellular uptake is often inefficient. Here, the authors show that reversible covalent warhead chemistry improves PROTAC intracellular accumulation and target engagement, and develop a dual ...
Wen-Hao Guo   +18 more
doaj   +1 more source

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

open access: yes, 2018
Bruton’s tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively.
Liming Dong (734480)   +24 more
core   +2 more sources

High-throughput screen reveals novel resistance mechanisms of Bruton’s Tyrosine Kinase to targeted therapeutics [PDF]

open access: yes, 2023
Tyrosine kinase inhibitors (TKIs) are a burgeoning class of therapeutics that has revolutionized the treatment of leukemias and lymphomas. These small molecules potently antagonize the tyrosine kinases involved in malignant signal transduction pathways ...
Desautelle, Joseph Edward
core   +1 more source

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

open access: yesHaematologica, 2019
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor,
Debora Soncini   +24 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination

open access: yesActa Neuropathologica Communications, 2023
Bruton’s tyrosine kinase (BTK) is an emerging target in multiple sclerosis (MS). Alongside its role in B cell receptor signaling and B cell development, BTK regulates myeloid cell activation and inflammatory responses. Here we demonstrate efficacy of BTK
Kirsten Scarlett Evonuk   +18 more
doaj   +1 more source

Antithrombotic prophylaxis in patients treated with Bruton’s tyrosine kinase inhibitors [PDF]

open access: yes, 2023
There is an increased risk of atrial fibrillation in patients treated with Bruton’s tyrosine kinase inhibitors such as ibrutinib or acalabrutinib. The risk of this complication, as in the general population, increases with the age of patients and the ...
Szmit, Sebastian; Department of Cardio-Oncology, Centre of Postgraduate Medical Education, Institute of Hematology and Transfusion Medicine in Warsaw, Poland; Department of Oncological Diagnostics and Cardio-Oncology, The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,, Poland
core   +1 more source

Development of an Efficient Manufacturing Process for Reversible Bruton’s Tyrosine Kinase Inhibitor GDC-0853

open access: yes, 2018
Efforts toward the process development of reversible Bruton’s tyrosine kinase (BTK) inhibitor GDC-0853 (1) are described. A practical synthesis of GDC-0853 was accomplished via a key highly regioselective Pd-catalyzed C–N coupling of tricyclic lactam 5 ...
Sushant Malhotra (1784344)   +12 more
core   +1 more source

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy